[H-3] Substance P

Substance P is an 11-amino-acid neuropeptide in the tachykinin family that acts as a key neurotransmitter and neuromodulator in pain transmission, inflammation, and smooth muscle regulation. It is predominantly expressed in the central nervous system (such as the spinal dorsal horn, amygdala, and basal ganglia) and within primary sensory C-fibers of the peripheral nervous system.

Substance P interacts with the neurokinin 1 (NK1) receptor by using its conserved C-terminal motif to bind deeply within a pocket formed by the receptor's transmembrane helices and extracellular loops. This high-affinity binding triggers a conformational change that couples the receptor primarily to Gaq/11 proteins, initiating downstream IP3/DAG and calcium signaling cascades. Following activation, the receptor-ligand complex undergoes b-arrestin–mediated endocytosis, which terminates acute cell-surface signaling and redirects the complex into endosomes for sustained intracellular signaling or degradation.

Substance P serves as a key transmitter in nociceptive pathways, transmitting pain signals from peripheral nerve terminals to the central nervous system. In response to tissue injury, it triggers neurogenic inflammation by causing microvascular plasma extravasation, mast cell degranulation, and vasodilation. Additionally, it accelerates wound healing and tissue repair by stimulating macrophage activity, cell proliferation, and the migration of keratinocytes and endothelial cells.

Upon binding substance P, the NK1 receptor primarily couples to Gq/11 proteins, activating phospholipase C (PLC) to cleave membrane lipids into IP3 (which mobilizes intracellular calcium) and DAG (which activates protein kinase C). Simultaneously, in a cell-type–dependent manner, activated NK1 can dually couple to Gs proteins to stimulate adenylyl cyclase, elevating cyclic AMP cAMP levels and activating protein kinase A (PKA). Together, these convergent signaling cascades drive downstream physiological functions such as nociceptive signaling, smooth muscle contraction, and neurogenic inflammation.

Substance P exhibits high selectivity for the NK1 receptor because its C-terminal amino acid sequence fits precisely into a distinct binding pocket formed by the extracellular loops and transmembrane helices of NK1. In contrast, NK2 and NK3 receptors have key structural variations in these contact residues that optimize them instead for their primary endogenous ligands, neurokinin A and neurokinin B, respectively. This evolutionary divergence in binding pocket microenvironments reduces the thermodynamic stability and binding affinity of substance P at NK2 and NK3 sites.

Dysregulation of substance P and its preferred neurokinin-1 (NK1) receptor is implicated in conditions involving chronic pain, neurogenic inflammation, and emesis, such as fibromyalgia, chemotherapy-induced nausea and vomiting (CINV), and inflammatory bowel disease. It also plays a key role in central nervous system disorders like depression, anxiety, and PTSD, where substance P signaling is heightened in stress-responsive brain regions.

Yes, several therapeutic NK1 receptor antagonists—such as aprepitant, fosaprepitant, netupitant, and rolapitant—are clinically approved to block substance P pathways. By selectively preventing substance P from binding to NK1 receptors in the central and peripheral nervous systems, these medications effectively prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV) as well as postoperative emesis.